Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

SAR439459

Powder for solution for infusion; IV infusion

DRUG

Placebo

Solution for infusion; IV infusion

Trial Locations (13)

2145

Westmead Hospital_Site Number :0360003, Westmead

3168

Department of Medicine/ School of Clinical Sciences at Monash Health Monash University_246 Clayton Road_Site Number :0360002, Clayton

21205

Kennedy Krieger Institute_Site number 8400004, Baltimore

37232

Vanderbilt University Site Number : 8400011, Nashville

45229

Cincinnati Children's Hospital Medical Center Site Number : 8400010, Cincinnati

46202

Indiana University School of Medicine_Site Number: 8400002, Indianapolis

69003

Hopital Edouard Herriot _Site Number :2500002, Lyon

75010

Hopital Lariboisiere_Site Number :2500001, Paris

77030

Baylor College of Medicine - Site Number:8400003, Houston

90095

UCLA Health_Site Number: 8400006, Los Angeles

06510

Yale University - Site Number:8400007, New Haven

L6M 1M1

Bone Research and Education Centre_Site Number :1240003, Oakville

M5G 2C4

Toronto general Hospital_Site Number :1240002, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY